Australia's Pharmaceutical Benefits Advisory Committee (PBAC) has recommended that Hospira's biosimilar infliximab product Inflectra should be listed on the Pharmaceutical Benefits Scheme. And in a highly controversial move, the PBAC has also said that Inflectra should be "a"-flagged, meaning that it can be substituted by pharmacists for the originator drug, Johnson & Johnson's Remicade.
The PBAC has lost no time in seeking a listing for Inflectra: the product has only just been approved by the Therapeutic Goods Administration as the first biosimilar infliximab...